Scholarlink

<p>Dendritic cell-targeting mRNA vaccines exhibit robust antitumor immune activation, however, their therapeutic efficacy remains unsatisfactory due to multiple delivery challenges, including carrier complexity, biomaterial toxicity, nucleic acid instability, and endosomal entrapment, which collectively compromise both safety and treatment outcomes. Here, we report the construction of poly T-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles to condense an HCC-specific <i>GPC3</i> mRNA with a unique poly(A) tail via hydrogen bonding interactions between A-T base pairs, affording P-(H)-m that further undergoes endoplasmic reticulum membrane camouflage to produce the target biomimetic vaccine, P-(H)-m@EMLN. The endoplasmic reticulum membrane enables P-(H)-m@EMLN with simultaneously enhanced endosomal escape properties and immunogenicity, which leads to a high tumor inhibition ratio (TIR) of 98.8% and long-term immunity activation in a Hepa1-6 tumor-bearing mouse model. Overall, this study reports the mRNA vaccine, P-(H)-m@EMLN via hydrogen bonding interactions between the poly T sequence of polymeric carrier and poly A tail of mRNA for robust immunotherapy of hepatocellular carcinoma.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An endoplasmic reticulum membrane-mimetic GPC3 mRNA nanovaccine for specific immunotherapy of hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月20日

查看全文
  • Tian Zeng,
  • Qing Gao,
  • Jun Qu,
  • Runshu Fu,
  • Cong Huang,
  • Yuqing Wang,
  • Zhuoyi Rong,
  • Pei Guo,
  • Haitao Zhang,
  • Hua Wei,
  • Cui-Yun Yu

摘要

Dendritic cell-targeting mRNA vaccines exhibit robust antitumor immune activation, however, their therapeutic efficacy remains unsatisfactory due to multiple delivery challenges, including carrier complexity, biomaterial toxicity, nucleic acid instability, and endosomal entrapment, which collectively compromise both safety and treatment outcomes. Here, we report the construction of poly T-modified poly (lactic-co-glycolic acid) (PLGA) nanoparticles to condense an HCC-specific GPC3 mRNA with a unique poly(A) tail via hydrogen bonding interactions between A-T base pairs, affording P-(H)-m that further undergoes endoplasmic reticulum membrane camouflage to produce the target biomimetic vaccine, P-(H)-m@EMLN. The endoplasmic reticulum membrane enables P-(H)-m@EMLN with simultaneously enhanced endosomal escape properties and immunogenicity, which leads to a high tumor inhibition ratio (TIR) of 98.8% and long-term immunity activation in a Hepa1-6 tumor-bearing mouse model. Overall, this study reports the mRNA vaccine, P-(H)-m@EMLN via hydrogen bonding interactions between the poly T sequence of polymeric carrier and poly A tail of mRNA for robust immunotherapy of hepatocellular carcinoma.